Community curated by people like you

TRUE Capital Management stories

Nov 5, 2026

Alethio Therapeutics raises $90M Series A for rare blood cancer antibody

Oxford spinout Alethio Therapeutics secured $90 million in Series A funding to advance an antibody treatment for myeloproliferative neoplasms, a group of rare blood cancers.

Nov 5, 2026·2 sources

00

Top claims

▪Existing myeloproliferative neoplasm treatments include frequent blood withdrawals, hydroxyurea, interferon therapies, JAK inhibitors such as Jakafi, and Takeda's newly approved medicine Mimrylo for polycythemia vera
▪Alethio Therapeutics chief executive officer Rohit Batta stated that existing treatments fail to help the majority of patients with myeloproliferative neoplasms
▪Alethio said ATX-011 targets G6b, a protein receptor expressed on platelets and bone marrow cells that induce myeloproliferative neoplasms or cause bone marrow scarring

Topics

Targeted cancer therapy Venture capital funding Cancer & Oncology Biotech innovation Drug development Biotech startup Rare diseases Hematology & Blood Cancers

Related entities